225 related articles for article (PubMed ID: 23122325)
1. Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.
Fox CB; Barnes V L; Evers T; Chesko JD; Vedvick TS; Coler RN; Reed SG; Baldwin SL
Influenza Other Respir Viruses; 2013 Sep; 7(5):815-26. PubMed ID: 23122325
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
[TBL] [Abstract][Full Text] [Related]
3. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
Deng J; Cai W; Jin F
Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
[TBL] [Abstract][Full Text] [Related]
4. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
Chada KE; Forshee R; Golding H; Anderson S; Yang H
Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
[TBL] [Abstract][Full Text] [Related]
6. Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family.
Fox CB; Van Hoeven N; Granger B; Lin S; Guderian JA; Hartwig A; Marlenee N; Bowen RA; Soultanov V; Carter D
Phytomedicine; 2019 Nov; 64():152927. PubMed ID: 31465981
[TBL] [Abstract][Full Text] [Related]
7. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.
Clegg CH; Roque R; Perrone LA; Rininger JA; Bowen R; Reed SG
PLoS One; 2014; 9(2):e88979. PubMed ID: 24551202
[TBL] [Abstract][Full Text] [Related]
8. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.
Treanor JJ; Chu L; Essink B; Muse D; El Sahly HM; Izikson R; Goldenthal KL; Patriarca P; Dunkle LM
Vaccine; 2017 Feb; 35(6):923-928. PubMed ID: 28089141
[TBL] [Abstract][Full Text] [Related]
9. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.
Klucker MF; Dalençon F; Probeck P; Haensler J
J Pharm Sci; 2012 Dec; 101(12):4490-500. PubMed ID: 22941944
[TBL] [Abstract][Full Text] [Related]
10. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.
Lau YF; Tang LH; McCall AW; Ooi EE; Subbarao K
J Virol; 2010 Sep; 84(17):8639-49. PubMed ID: 20538850
[TBL] [Abstract][Full Text] [Related]
11. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
12. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
13. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
14. Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.
Akamatsu MA; Sakihara VA; Carvalho BP; de Paiva Abrantes A; Takano MAS; Adami EA; Yonehara FS; Dos Santos Carneiro P; Rico S; Schanoski A; Meros M; Simpson A; Phan T; Fox CB; Ho PL
PLoS One; 2020; 15(6):e0233632. PubMed ID: 32492039
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.
Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
Vaccine; 2011 Nov; 29(51):9563-72. PubMed ID: 21906648
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
17. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
[TBL] [Abstract][Full Text] [Related]
18. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
[TBL] [Abstract][Full Text] [Related]
19. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
20. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
